In Q2 2026, Cytek Biosciences exceeded revenue expectations driven by robust sales of its Full Spectrum Profiling-based cytometry instruments. Despite this growth, the company reported a net loss due to elevated research and development spending and supply chain cost pressures affecting margins. Cytek’s integrated platform approach, combining advanced instrumentation with proprietary software and consumables, supports expanding recurring revenue streams across pharmaceutical, academic, and clinical research segments. Key execution risks include regulatory complexities, competitive intensity from established incumbents, elongated institutional sales cycles, and capital requirements for scaling manufacturing and global expansion.